DSM Commences Tender Offer for Martek

The Martek board of directors has unanimously determined that, among other things, the offer is fair to and in the best interests of Martek’s stockholders and unanimously recommends that Martek’s stockholders accept the offer and tender their shares.

1/13/2011 --- Royal DSM N.V. has announced that its indirect wholly-owned subsidiary, Greenback Acquisition Corporation, has commenced its tender offer for all outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share.

The tender offer is being made in connection with the Agreement and Plan of Merger, dated as of 20 December 2010, by and among DSM, Greenback Acquisition Corporation and Martek, which DSM and Martek announced on 21 December 2010.

The Martek board of directors has unanimously determined that, among other things, the offer is fair to and in the best interests of Martek’s stockholders and unanimously recommends that Martek’s stockholders accept the offer and tender their shares.

The tender offer is scheduled to expire at 5:00 p.m. (New York City time) on Friday, 18 February 2011, unless the offer is extended.

Complete terms and conditions of the tender offer are set forth in the Offer to Purchase, Letter of Transmittal and other related materials that will be filed by DSM and Greenback Acquisition Corporation with the SEC on 13 January 2011. In addition, on 13 January 2011, Martek will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC relating to the offer. Copies of the Offer to Purchase, Letter of Transmittal and other related materials are available free of charge from MacKenzie Partners, Inc., the information agent for the tender offer, toll-free at (800) 322-2885. The dealer manager for the tender offer is J.P. Morgan Securities LLC. Citibank, N.A. is acting as depositary for the tender offer.